Pharmaceutical companies are investing heavily in targeted medicines, and with good reason. However, to increase the probability of a drug making it from Phase I to market and to succeed in developing targeted medicines, companies need robust and efficient biomarker strategies. As a result, Identification of biomarkers that can be studied throughout the development process requires technologies that are both feasible and cost-effective for large patient populations.
Against this background, The Boston Biomarker and CDx Summit taking place on 24th - 25th October 2019 will address the challenges from drug discovery to commercialization. Pharma and biotech will present and share their expertise on how to make smart decisions about identifying novel biomarkers, clinical trial design, assays, technology platforms and CDx development.
Expect to meet the Who's Who of the industry at this unique event.